IL123467A0 - Methods and compositions for the selective modification of nucleic acids - Google Patents

Methods and compositions for the selective modification of nucleic acids

Info

Publication number
IL123467A0
IL123467A0 IL12346796A IL12346796A IL123467A0 IL 123467 A0 IL123467 A0 IL 123467A0 IL 12346796 A IL12346796 A IL 12346796A IL 12346796 A IL12346796 A IL 12346796A IL 123467 A0 IL123467 A0 IL 123467A0
Authority
IL
Israel
Prior art keywords
compositions
methods
nucleic acids
selective modification
blood
Prior art date
Application number
IL12346796A
Other languages
English (en)
Original Assignee
Pentose Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentose Pharmaceuticals Inc filed Critical Pentose Pharmaceuticals Inc
Publication of IL123467A0 publication Critical patent/IL123467A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
IL12346796A 1995-08-29 1996-08-29 Methods and compositions for the selective modification of nucleic acids IL123467A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/521,245 US6114108A (en) 1995-08-29 1995-08-29 Methods and compositions for the selective modification of viral nucleic acids
PCT/US1996/014040 WO1997007674A1 (en) 1995-08-29 1996-08-29 Methods and compositions for the selective modification of nucleic acids

Publications (1)

Publication Number Publication Date
IL123467A0 true IL123467A0 (en) 1998-09-24

Family

ID=24075988

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12346796A IL123467A0 (en) 1995-08-29 1996-08-29 Methods and compositions for the selective modification of nucleic acids

Country Status (18)

Country Link
US (1) US6114108A (xx)
EP (2) EP0915648B1 (xx)
JP (2) JP2001520635A (xx)
KR (1) KR100486765B1 (xx)
AT (2) ATE217144T1 (xx)
AU (1) AU694892B2 (xx)
BR (1) BR9610306A (xx)
CA (1) CA2230671A1 (xx)
DE (2) DE69621161T2 (xx)
DK (1) DK0915648T3 (xx)
ES (1) ES2173314T3 (xx)
HK (1) HK1042254A1 (xx)
IL (1) IL123467A0 (xx)
NO (1) NO980881L (xx)
NZ (1) NZ316787A (xx)
PL (1) PL187759B1 (xx)
PT (1) PT915648E (xx)
WO (1) WO1997007674A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
DE19633684A1 (de) * 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
CA2317603A1 (en) 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
CA2332314A1 (en) 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
WO2000018969A1 (en) * 1998-09-25 2000-04-06 Pentose Pharmaceuticals, Inc. Methods to selectively inactivate viruses in biological compositions
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2002243363A1 (en) * 2000-11-06 2002-07-24 V.I. Technologies, Inc. Use of aziridino-compounds in the treatment of immune dysfunctions
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US20030127603A1 (en) * 2001-05-15 2003-07-10 Bernard Horowitz Apparatus for the inactivation of pathogens in protein-containing fluids and uses thereof
WO2003066806A2 (en) * 2001-11-06 2003-08-14 V.I. Technologies, Inc. Therapeutic use of aziridino compounds
AU2002359918A1 (en) 2001-12-28 2003-07-24 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
CN102046006B (zh) 2008-04-09 2014-09-24 塞鲁斯公司 用于红细胞病原体灭活的改进猝灭方法
SG11201407619SA (en) * 2012-06-01 2014-12-30 Boehringer Ingelheim Vetmed Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
KR20180091824A (ko) 2015-11-01 2018-08-16 글리코백, 엘엘씨 바이러스 비함유 세포주 및 이를 획득하기 위한 방법
CA3022603A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
KR102198877B1 (ko) 2019-07-16 2021-01-05 정소영 블루 라이트 차단 필터
CN113322252A (zh) * 2020-12-28 2021-08-31 广州凯普医药科技有限公司 一种拭子样本保存液

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
RU594771C (ru) * 1973-05-07 1993-07-07 Всесоюзный научно-исследовательский ящурный институт Средство дл инактивации вирусов при изготовлении противовирусных препаратов
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
RU1768636C (ru) * 1989-08-16 1992-10-15 Всесоюзный научно-исследовательский ветеринарный институт птицеводства Способ получени антигена вируса болезни Гамборо
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JPH05502183A (ja) * 1990-09-04 1993-04-22 シャンブロム，エドワード 血液、組織および生物体液の保存
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
FR2679253B1 (fr) * 1991-07-15 1994-09-02 Pasteur Institut Proteines de resistance a la cycloheximide. utilisation comme marqueur de selection par exemple pour controler le transfert d'acides nucleiques.
EP0612532A3 (en) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
AU722811B2 (en) * 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents

Also Published As

Publication number Publication date
EP1129728A1 (en) 2001-09-05
EP1129728B1 (en) 2006-03-08
JP2001520635A (ja) 2001-10-30
EP0915648A4 (xx) 1999-05-19
KR19990044303A (ko) 1999-06-25
ES2173314T3 (es) 2002-10-16
US6114108A (en) 2000-09-05
EP0915648B1 (en) 2002-05-08
HK1042254A1 (zh) 2002-08-09
PL187759B1 (pl) 2004-10-29
ATE319483T1 (de) 2006-03-15
AU694892B2 (en) 1998-07-30
DE69635871D1 (de) 2006-05-04
DE69621161D1 (de) 2002-06-13
PT915648E (pt) 2002-09-30
NZ316787A (en) 1999-11-29
PL325338A1 (en) 1998-07-20
KR100486765B1 (ko) 2005-09-02
DE69635871T2 (de) 2007-05-24
DK0915648T3 (da) 2002-08-26
BR9610306A (pt) 1999-07-06
NO980881D0 (no) 1998-02-27
ATE217144T1 (de) 2002-05-15
JP2003176238A (ja) 2003-06-24
EP0915648A1 (en) 1999-05-19
DE69621161T2 (de) 2002-11-21
NO980881L (no) 1998-04-27
CA2230671A1 (en) 1997-03-06
AU6909996A (en) 1997-03-19
WO1997007674A1 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
IL123467A0 (en) Methods and compositions for the selective modification of nucleic acids
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DE69636734D1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
FI962613A (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
AU7814498A (en) Multivalent (in ovo) avian vaccine
HU901585D0 (en) Method for treatment of viral infections using functional derivatives of icam-1
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
WO2002096471A3 (en) Viral inactivation process using antioxidant
PT600396E (pt) Vacinas contra protozoarios intestinais
DE10075036I2 (de) Impfstoff und Diagnostikum f}r den Schweine-Cholera-Virus.
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
DK0684842T3 (da) Præparat til behandling af tumorer og immunisering af organismer over for tumorer
DE69111457T2 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
FR2633527B1 (fr) Appareil semi-continu de cuisson, de pasteurisation ou de sterilisation
EP0866654A4 (en) METHOD OF TREATING HEPATITIS VIRUS INFECTION
PT92788A (pt) Processo para a preparacao de substancias naturais isentas de virus

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees